{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:08:18Z","timestamp":1787508498058,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03487-6","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:17:40Z","timestamp":1749014260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Lin-Yu","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Chen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"8 suppl","key":"3487_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/cncr.23844","volume":"113","author":"BO Anderson","year":"2008","unstructured":"Anderson, B. O. et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the breast health global initiative global summit 2007. Cancer 113(8 suppl), 2221\u20132243. https:\/\/doi.org\/10.1002\/cncr.23844 (2008).","journal-title":"Cancer"},{"key":"3487_CR2","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert, C., Cornelia, L. & Andrew, T. Gunter von M. Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies. Lancet 389, 2430\u20132442. https:\/\/doi.org\/10.1016\/S0140-6736(16)32454-0 (2017).","journal-title":"Lancet"},{"issue":"9","key":"3487_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of Estrogen receptor (ER)- negative, progesterone receptor (PR)- negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9), 1721\u20131728. https:\/\/doi.org\/10.1002\/cncr.22618 (2007).","journal-title":"Cancer"},{"issue":"15S","key":"3487_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1200\/jco.2008.26.15_suppl.1010","volume":"26","author":"F Heitz","year":"2008","unstructured":"Heitz, F., Harter, P., Traut, A., Lueck, H. J. & Bois, A. D. Cerebral metastases (CM) in breast cancer (BC) with focus on triple- negative tumors. J. Clin. Oncol. 26(15S), 1010. https:\/\/doi.org\/10.1200\/jco.2008.26.15_suppl.1010 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"3487_CR5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1245\/s10434-016-5733-y","volume":"24","author":"CA Puig","year":"2017","unstructured":"Puig, C. A., Hoskin, T. L., Day, C. N., Habermann, E. B. & Boughey, J. C. National trends in the use of neoadjuvant chemotherapy for hormone Receptor-Negative breast cancer: A National Cancer data base study. Ann. Surg. Oncol. 24(5), 1242\u20131250. https:\/\/doi.org\/10.1245\/s10434-016-5733-y (2017).","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"3487_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdy537","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast Cancer 2017. Ann. Oncol. 28(8), 1700\u20131712. https:\/\/doi.org\/10.1093\/annonc\/mdy537 (2017).","journal-title":"Ann. Oncol."},{"key":"3487_CR7","doi-asserted-by":"publisher","first-page":"26406","DOI":"10.18632\/oncotarget.25413","volume":"9","author":"A Santonja","year":"2018","unstructured":"Santonja, A. et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget 9, 26406\u201326416. https:\/\/doi.org\/10.18632\/oncotarget.25413 (2018).","journal-title":"Oncotarget"},{"issue":"3","key":"3487_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12282-018-00934-3","volume":"26","author":"Z Bi","year":"2019","unstructured":"Bi, Z. et al. Neoadjuvant chemotherapy and timing of Sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axillary. Breast Cancer. 26(3), 373\u2013377. https:\/\/doi.org\/10.1007\/s12282-018-00934-3 (2019).","journal-title":"Breast Cancer"},{"key":"3487_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl. J. Med. 387, 9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690 (2022).","journal-title":"N Engl. J. Med."},{"key":"3487_CR10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1001\/jamaoncol.2022.4175","volume":"8","author":"A Prat","year":"2022","unstructured":"Prat, A. et al. An overview of clinical development of agents for metastatic or advanced breast Cancer without ERBB2 amplification (HER2-Low). JAMA Oncol. 8, 1676\u20131687. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4175 (2022).","journal-title":"JAMA Oncol."},{"issue":"16","key":"3487_CR11","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1002\/cncr.35323","volume":"130","author":"F Schettini","year":"2024","unstructured":"Schettini, F. et al. Characterization of HER2-low breast cancer in young women with germline BRCA1\/2 pathogenetic variants: results of a large international retrospective cohort study. Cancer 130(16), 2746\u20132762. https:\/\/doi.org\/10.1002\/cncr.35323 (2024).","journal-title":"Cancer"},{"issue":"1","key":"3487_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13058-023-01639-y","volume":"25","author":"XE Hu","year":"2023","unstructured":"Hu, X. E. et al. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res. 25(1), 34. https:\/\/doi.org\/10.1186\/s13058-023-01639-y (2023).","journal-title":"Breast Cancer Res."},{"key":"3487_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert, C. et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 22, 1151\u20131161. https:\/\/doi.org\/10.1016\/S1470-2045(21)00301-6 (2021).","journal-title":"Lancet Oncol."},{"issue":"8","key":"3487_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/jamaoncol.2022.2286","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Prognostic and biologic significance of ERBB2-Low expression in Early-Stage breast Cancer. JAMA Oncol. 8(8), 1177\u20131183. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2286 (2022).","journal-title":"JAMA Oncol."},{"issue":"11","key":"3487_CR15","doi-asserted-by":"publisher","first-page":"103973","DOI":"10.1016\/j.esmoop.2024.103973","volume":"9","author":"AS Raghavendra","year":"2024","unstructured":"Raghavendra, A. S. et al. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status. ESMO Open. 9(11), 103973. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103973 (2024).","journal-title":"ESMO Open."},{"issue":"2","key":"3487_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-024-07317-7","volume":"206","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Lu, H. & Zhang, Y. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res. Treat. 206(2), 387\u2013395. https:\/\/doi.org\/10.1007\/s10549-024-07317-7 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"3487_CR17","doi-asserted-by":"publisher","unstructured":"Zhang, S. Y. et al. Clinicopathological characteristics of breast cancer patients with HER-2 low expression receiving neoadjuvant therapy. Oncology 102(2), 122\u2013130. https:\/\/doi.org\/10.1159\/000533787 (2024).","DOI":"10.1159\/000533787"},{"issue":"11","key":"3487_CR18","doi-asserted-by":"publisher","first-page":"106970","DOI":"10.1016\/j.ejso.2023.06.022","volume":"49","author":"GS Zhong","year":"2023","unstructured":"Zhong, G. S. et al. Pathological complete response rate and clinical outcome after neoadjuvant therapy of HER2-low breast cancer: a National Cancer database analysis. Eur. J. Surg. Oncol. 49(11), 106970. https:\/\/doi.org\/10.1016\/j.ejso.2023.06.022 (2023).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"3","key":"3487_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12282-022-01431-4","volume":"30","author":"JJ Li","year":"2023","unstructured":"Li, J. J., Yu, Y. & Ge, J. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer. 30(3), 364\u2013378. https:\/\/doi.org\/10.1007\/s12282-022-01431-4 (2023).","journal-title":"Breast Cancer"},{"issue":"4","key":"3487_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/10815589231151232","volume":"71","author":"WJ Shi","year":"2023","unstructured":"Shi, W. J. et al. Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. J. Investig Med. 71(4), 384\u2013393. https:\/\/doi.org\/10.1177\/10815589231151232 (2023).","journal-title":"J. Investig Med."},{"issue":"8","key":"3487_CR21","first-page":"3571","volume":"13","author":"YJ Li","year":"2023","unstructured":"Li, Y. J. et al. Effect of HER2-lowpositive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study. Am. J. Cancer Res. 13(8), 3571\u20133581 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"3487_CR22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366. https:\/\/doi.org\/10.1200\/JCO.19.02309 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"3487_CR23","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1158\/1078-0432.CCR-05-0449","volume":"11","author":"SJ Kim","year":"2005","unstructured":"Kim, S. J. et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 11(23), 8425\u20138430. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0449 (2005).","journal-title":"Clin. Cancer Res."},{"key":"3487_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen, T. O. et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast Cancer working group. J. Natl. Cancer Inst. 113, 808\u2013819. https:\/\/doi.org\/10.1093\/jnci\/djaa201 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"3487_CR25","doi-asserted-by":"publisher","first-page":"575317","DOI":"10.3389\/fonc.2020.575317","volume":"10","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Analysis of CK5\/6 and EGFR and its effect on prognosis of triple negative breast Cancer. Front. Oncol. 10, 575317. https:\/\/doi.org\/10.3389\/fonc.2020.575317 (2020).","journal-title":"Front. Oncol."},{"issue":"4","key":"3487_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2559.2007.02638.x","volume":"50","author":"EA Rakha","year":"2007","unstructured":"Rakha, E. A. et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50(4), 434\u2013438. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02638.x (2007).","journal-title":"Histopathology"},{"issue":"6","key":"3487_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyad009","volume":"53","author":"WW Xu","year":"2023","unstructured":"Xu, W. W. et al. HER2-low status May predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study. Jpn J. Clin. Oncol. 53(6), 463\u2013471. https:\/\/doi.org\/10.1093\/jjco\/hyad009 (2023).","journal-title":"Jpn J. Clin. Oncol."},{"issue":"4","key":"3487_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12094-023-03318-y","volume":"26","author":"XL Yi","year":"2024","unstructured":"Yi, X. L., Hu, S. S., Ma, M. L., Huang, D. S. & Zhang, Y. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer. Clin. Transl Oncol. 26(4), 880\u2013890. https:\/\/doi.org\/10.1007\/s12094-023-03318-y (2024).","journal-title":"Clin. Transl Oncol."},{"key":"3487_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","volume":"11","author":"S Kang","year":"2022","unstructured":"Kang, S. et al. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur. J. cancer. 11, 30\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.031 (2022).","journal-title":"Eur. J. cancer"},{"issue":"1","key":"3487_CR30","doi-asserted-by":"publisher","first-page":"16899","DOI":"10.1038\/s41598-024-67795-z","volume":"14","author":"Z Shi","year":"2024","unstructured":"Shi, Z. et al. Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy. Sci. Rep. 14(1), 16899. https:\/\/doi.org\/10.1038\/s41598-024-67795-z (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"3487_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAS.0000000000002139","volume":"48","author":"L Wu","year":"2024","unstructured":"Wu, L. et al. Prognostic value of Immunohistochemistry-based subtyping before and after neoadjuvant chemotherapy in patients with Triple-negative breast Cancer. Am. J. Surg. Pathol. 48(1), 27\u201335. https:\/\/doi.org\/10.1097\/PAS.0000000000002139 (2024).","journal-title":"Am. J. Surg. Pathol."},{"key":"3487_CR32","doi-asserted-by":"publisher","unstructured":"Atoui, A. et al. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 expression as a predictive value for pathological complete response following neoadjuvant chemotherapy: Experience from a tertiary care center in Lebanon. Int. J. Breast Cancer. https:\/\/doi.org\/10.1155\/2022\/1218128  (2022).","DOI":"10.1155\/2022\/1218128"},{"key":"3487_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.coc.0000204405.96572.f9","volume":"29","author":"C Bozzetti","year":"2006","unstructured":"Bozzetti, C. et al. Evaluation of HER-2\/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am. J. Clin. Oncol. 29, 171\u2013177. https:\/\/doi.org\/10.1097\/01.coc.0000204405.96572.f9 (2006).","journal-title":"Am. J. Clin. Oncol."},{"key":"3487_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1634\/theoncologist.2008-0073","volume":"13","author":"F Penault-Llorca","year":"2008","unstructured":"Penault-Llorca, F. et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, Cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 13, 1235\u20131245. https:\/\/doi.org\/10.1634\/theoncologist.2008-0073 (2008).","journal-title":"Oncologist"},{"issue":"6","key":"3487_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1600-0463.2008.01024.x","volume":"116","author":"H Nalwoga","year":"2008","unstructured":"Nalwoga, H. et al. Expression of EGFR and Ckit is associated with the basal-like phenotype in breast carcinomas of African women. Apmis 116(6), 515\u2013525. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.01024.x (2008).","journal-title":"Apmis"},{"issue":"1","key":"3487_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00795-015-0109-0","volume":"49","author":"T Maeda","year":"2016","unstructured":"Maeda, T. et al. Immunohistochemical co-expression status of cytokeratin 5\/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med. Mol. Morphol. 49(1), 11\u201321. https:\/\/doi.org\/10.1007\/s00795-015-0109-0 (2016).","journal-title":"Med. Mol. Morphol."},{"key":"3487_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.anndiagpath.2017.01.009","volume":"28","author":"AE Abdelrahman","year":"2017","unstructured":"Abdelrahman, A. E., Rashed, H. E., Abdelgawad, M. & Abdelhamid, M. I. Prognostic impact of EGFR and cytokeratin 5\/6 immunohistochemical expression in triple-negative breast cancer. Ann. Diagn. Pathol. 28, 43\u201353. https:\/\/doi.org\/10.1016\/j.anndiagpath.2017.01.009 (2017).","journal-title":"Ann. Diagn. Pathol."},{"key":"3487_CR38","doi-asserted-by":"publisher","first-page":"175883592199667","DOI":"10.1177\/1758835921996673","volume":"13","author":"J Hong","year":"2021","unstructured":"Hong, J., Tong, Y. W., He, J. R., Chen, X. S. & Shen, K. W. Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.ther. Adv. Med. Oncol. 13, 1758835921996673. https:\/\/doi.org\/10.1177\/1758835921996673 (2021).","journal-title":"Adv. Med. Oncol."},{"issue":"12","key":"3487_CR39","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron, A. U. et al. Association of low nodal positivity rate among patients with ERBB2-Positive or Triple-Negative breast Cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 153(12), 1120\u20131126 (2018).","journal-title":"JAMA Surg."},{"issue":"7","key":"3487_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros, A. B. et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 152(7), 665\u2013670. https:\/\/doi.org\/10.1001\/jamasurg.2017.0562 (2017).","journal-title":"JAMA Surg."},{"issue":"11","key":"3487_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/CM9.0000000000002849","volume":"137","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Association of a complete breast cancer pathologic response with axillary lymph node metastasis via neoadjuvant chemotherapy: results from the CSBrS-012 study. Chin. Med. J. 137(11), 1369\u20131371. https:\/\/doi.org\/10.1097\/CM9.0000000000002849 (2024).","journal-title":"Chin. Med. J."},{"key":"3487_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N Engl. J. Med. 382, 810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549 (2020).","journal-title":"N Engl. J. Med."},{"issue":"19","key":"3487_CR43","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3390\/cancers16193389","volume":"16","author":"E Karci","year":"2024","unstructured":"Karci, E. et al. Neoadjuvant pembrolizumab plus chemotherapy in Early-Stage Triple-Negative breast cancer: A nationwide retrospective Turkish oncology group study. Cancers (Basel). 16(19), 3389. https:\/\/doi.org\/10.3390\/cancers16193389 (2024).","journal-title":"Cancers (Basel)"},{"key":"3487_CR44","doi-asserted-by":"publisher","unstructured":"Wei, Y. H., Wu, Y., Luo, Y. & Ma, F. Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1\/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis. Crit. Rev. Oncol. Hematol. 196104309. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104309 (2024).","DOI":"10.1016\/j.critrevonc.2024.104309"},{"key":"3487_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","volume":"48","author":"L Gerratana","year":"2016","unstructured":"Gerratana, L., Fanotto, V., Pelizzari, G., Agostinetto, E. & Puglisi, F. Do platinum salts fit all triple negative breast cancers? Cancer Treat. Rev. 48, 34\u201341. https:\/\/doi.org\/10.1016\/j.ctrv.2016.06.004 (2016).","journal-title":"Cancer Treat. Rev."},{"issue":"14","key":"3487_CR46","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/ijms20143390","volume":"20","author":"M Garutti","year":"2019","unstructured":"Garutti, M. et al. Platinum salts in patients with breast cancer: A focus on predictive factors. Int. J. Mol. Sci. 20(14), 3390. https:\/\/doi.org\/10.3390\/ijms20143390 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"3487_CR47","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.esmoop.2024.103700","volume":"9","author":"R Mazzeo","year":"2024","unstructured":"Mazzeo, R. et al. Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology. ESMO Open. 9(10), 103700. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103700 (2024).","journal-title":"ESMO Open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03487-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03487-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03487-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:01:49Z","timestamp":1749402109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03487-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3487"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03487-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Tianjin Medical University Cancer Hospital. All methods were performed in accordance with the relevant guidelines and regulations. As this is a retrospective analysis, informed consent from patients was waived by the Ethics Committee of Tianjin Medical University Cancer Hospital. Authors had access to information that could identify individual participants during or after data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"19595"}}